FDA — authorised 11 July 1972
- Application: ANDA080500
- Marketing authorisation holder: SOLVAY
- Local brand name: RAUWOLFIA SERPENTINA
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 RAUWOLFIA SERPENTINA in United States
FDA authorised RAUWOLFIA SERPENTINA on 11 July 1972
Marketing authorisations
FDA
- Application: NDA009668
- Marketing authorisation holder: VALEANT PHARM INTL
- Local brand name: RAUWOLFIA SERPENTINA
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA083444
- Marketing authorisation holder: TABLICAPS
- Local brand name: RAUWOLFIA SERPENTINA
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA080498
- Marketing authorisation holder: HALSEY
- Local brand name: RAUWOLFIA SERPENTINA
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: NDA009477
- Marketing authorisation holder: BUNDY
- Local brand name: RAUWOLFIA SERPENTINA
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: NDA010581
- Marketing authorisation holder: PHYS PRODS VA
- Local brand name: HYSERPIN
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA080583
- Marketing authorisation holder: PVT FORM
- Local brand name: RAUWOLFIA SERPENTINA
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: NDA009278
- Marketing authorisation holder: PANRAY
- Local brand name: KOGLUCOID
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: NDA009926
- Marketing authorisation holder: FERNDALE LABS
- Local brand name: RAUSERPIN
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: NDA009273
- Marketing authorisation holder: IMPAX LABS
- Local brand name: RAUWOLFIA SERPENTINA
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: NDA009108
- Marketing authorisation holder: PAL PAK
- Local brand name: RAUVAL
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: NDA009255
- Marketing authorisation holder: FOREST PHARMS
- Local brand name: WOLFINA
- Indication: TABLET — ORAL
- Status: approved
FDA
- Status: approved
FDA
- Application: NDA008842
- Marketing authorisation holder: APOTHECON
- Local brand name: RAUDIXIN
- Indication: TABLET — ORAL
- Status: approved
Other Other approved in United States
Frequently asked questions
Is RAUWOLFIA SERPENTINA approved in United States?
Yes. FDA authorised it on 11 July 1972; FDA has authorised it; FDA has authorised it.
Who is the marketing authorisation holder for RAUWOLFIA SERPENTINA in United States?
SOLVAY holds the US marketing authorisation.